CAJ | 학술논문

目的探讨高迁移率族蛋白B1(HMGB1)在淋巴瘤患者中的表达及其意义.方法收集27例不同类型淋巴瘤患者化疗前后的血清样本,酶联免疫吸附法(ELISA)检测HMGB1水平,与35名健康对照进行比较,并对其表达水平变化与患者疗效及预后的关系进行分析.结果患者化疗前2天、化疗后第8天的HMGB1水平分别为(66.24±29.96)ng/ml、(48.63±23.69)ng/ml,高于对照组的(4.89±2.43)ng/ml(P＜ 0.001),化疗后HMGB1水平较化疗前降低(P=0.003),27例患者中有20例化疗后第8天HMGB1水平下降.化疗前后HMGB1水平比值与患者疗效有关(P=0.029),HMGB1比值≤1是淋巴瘤患者的不良预后因素(P=0.038).结论淋巴瘤患者血清HMGB1水平较健康人群高,检测其化疗前后水平变化有助于疗效判定及预后评估.
목적 탐토고천이솔족단백B1(HMGB1)재림파류환자중적표체급기의의.방법 수집27례불동류형림파류환자화료전후적혈청양본,매련면역흡부법(ELISA)검측HMGB1수평,여35명건강대조진행비교,병대기표체수평변화여환자료효급예후적관계진행분석.결과 환자화료전2천、화료후제8천적HMGB1수평분별위(66.24±29.96)ng/ml、(48.63±23.69)ng/ml,고우대조조적(4.89±2.43)ng/ml(P＜ 0.001),화료후HMGB1수평교화료전강저(P=0.003),27례환자중유20례화료후제8천HMGB1수평하강.화료전후HMGB1수평비치여환자료효유관(P=0.029),HMGB1비치≤1시림파류환자적불량예후인소(P=0.038).결론 림파류환자혈청HMGB1수평교건강인군고,검측기화료전후수평변화유조우료효판정급예후평고.
Objective To investigate the expression of high-mobility group box 1(HMGB1) protein in lymphoma patients and its clinical significance.Methods The pre-and post-chemotherapy serum samples from 27 lymphoma patients of different types were collected and the serum HMGB1 concentrations were determined with ELISA and compared to 35 normal individuals,the impact on serum HMGB1 levels and patients response and prognosis was analyzed.Results The serum HMGB1 levels (pre-and postchemotherapy) in lymphoma patient [(66.24 ± 29.96) ng/ml,(48.63 ± 23.69) ng/ml] were higher than those of controls' [(4.89 ± 2.43) ng/ml] (P ＜ 0.001),decreased serum HMGB1 levels on day 8 post-chemotherapy were observed in 20 out of 27 patients (P =0.003).The pre-and post-chemotherapy serum HMGB 1 level changes were associated with treatment response (P =0.029),and survival analysis showed the serum HMGB1 level changes had an impact on patient survival (P =0.038).Conclusion HMGB1 serum level is significantly elevated in lymphoma patients,determination of pre-and post-chemotherapy serum HMGB1 levels may aid response evaluation and prognosis assessment.